Lantheus Q2 Revenue Beats at $388M, Adjusted EPS $1.55; Guidance Pulled Amid $8B Curium Buyout
LNTH has more than doubled off its 52-week low of $47.25.
Summary
Lantheus reported Q2 2026 revenue of $388.2M and adjusted EPS of $1.55, beating expectations, but suspended guidance and the earnings call due to its pending $8 billion acquisition by Curium.
Key Events · Earnings and Guidance · LNTH
-
Q2 Revenue and EPS Beat
Worldwide revenue of $388.2 million grew 2.7% year-over-year, beating consensus by over $25 million. Adjusted diluted EPS of $1.55 exceeded expectations, though GAAP EPS of $1.11 declined slightly from $1.12 a year ago.
-
Guidance Suspended, No Call
Lantheus suspended its previously issued full-year 2026 financial guidance and will not host a conference call, citing the pending merger with Curium announced on August 3, 2026.
-
Merger Context Dominates
The results land three days after the definitive agreement to be acquired by Curium for $102.50 per share in cash plus up to $12.00 in CVRs, valuing the company at up to $8.0 billion. The stock is trading near the offer price, limiting standalone earnings impact.
-
Product Performance Mixed
PYLARIFY sales declined 4.1% to $240.4 million, while DEFINITY grew 5.2% to $88.3 million. Neuraceq contributed $39.6 million following the Lantheus Biosciences acquisition.
Analysis · LNTH · Life Sciences
Lantheus delivered a solid Q2, with revenue of $388.2 million beating consensus by over $25 million and adjusted EPS of $1.55 topping estimates. However, the company suspended its full-year 2026 guidance and canceled the earnings call, citing the pending $8 billion all-cash acquisition by Curium announced three days ago. The strong quarter reinforces the standalone value of the business, but the merger overhang means these results are unlikely to drive the stock independently — the $102.50 per share cash offer (plus up to $12 in CVRs) now anchors the valuation. Investors will focus on the merger timeline and any potential competing bids rather than the quarterly numbers.
At the time of this filing, LNTH was trading at $101.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $47.25 to $111.86. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.